Currently Enrolling Clinical Trials
Sponsored by Mirati
Phase 2 study of sitravatinib in combination for clear cell renal cell cancer
Phase 2 study of sitravatinib in combination with a checkpoint inhibitor for urothelial carcinoma
Phase 3 study of sitravatinib in combination with nivolumab for non-small cell lung cancer (NSCLC) (SAPPHIRE)
Phase 1/1b study of sitravatinib in combination with nivolumab and ipilimumab
KRAS G12C Inhibitor Adagrasib (MRTX849)
Sponsored by Mirati
Phase 1/2 study of MRTX849 in patients with cancer having a KRASG12C mutation (KRYSTAL-1)
Phase 1/2 study of MRTX849 in combination with TNO-155 in patients with cancer having a KRASG12C mutation (KRYSTAL-2)
Phase 2 study of MRTX849 in combination with pembrolizumab in NSCLC patients having a KRASG12C mutation (KRYSTAL-7)
Phase 3 study of MRTX849 with cetuximab vs chemotherapy in patients with CRC with KRASG12C mutation (KRYSTAL-10)
Phase 3 study of MRTX849 vs docetaxel in patients with NSCLC with KRASG12C mutation (KRYSTAL-12)
A Phase 1/1b study of MRTX849 in combination with BI 1701963 in patients with advanced solid tumors with KRASG12C mutation (KRYSTAL-14)
Sponsored by Mirati in collaboration with industry partners.
BeiGene Sponsored Trials
Phase 1b study of sitravatinib in combination for advanced solid tumors
Phase 1/2 study of sitravatinib monotherapy and in combination for HCC or GC/GEJC
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified healthcare professional.
To identify clinical trials that match your diagnosis, treatment history and location, call 1-844-893-5530 or use our online Study Locator.